Pediatric Vaccine

With the recent approval of the monoclonal antibodies palivizumab and nirsevimab and their encouraging results from a current phase III maternal immunization trial, respiratory syncytial virus morbidity and mortality will likely be significantly reduced. Respiratory syncytial virus (RSV) causes most lower respiratory tract infections (LRTI) in children and accounts for over 3.6 million hospital admissions...

When will the pandemic finally be over? Hopefully sooner than later, according to new modeling data. Although the Delta variant has caused COVID-19 to peak again, researchers from the COVID-19 Scenario Modeling Hub have projected a steady decline in COVID-19 cases and deaths in the United States over the next six months. The data predict...

Pfizer’s COVID-19 vaccine has proven efficacious in children between the ages of 5 and 11, according to research submitted to the U.S. Food and Drug Administration. While data have been released to health regulators on the efficacy of Pfizer’s vaccine in this age group, a formal application with the FDA to authorize its use is still...